Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results [Yahoo! Finance]
McKesson Corporation (MCK)
Last mckesson corporation earnings: 2/4 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.mckesson.com
Company Research
Source: Yahoo! Finance
-Presented preclinical data demonstrating the potential synergy between VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft at the ASGCT Annual Meeting; emphasizes VCN-01's potential in diverse chemotherapy combinations for improved efficacy in pancreatic cancer- - VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- - As of March 31, 2024, Theriva Biologics reports $18.3 million in cash, which is expected to provide runway into the first quarter of 2025- ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “In the first quarter we rep
Show less
Read more
Impact Snapshot
Event Time:
MCK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCK alerts
High impacting McKesson Corporation news events
Weekly update
A roundup of the hottest topics
MCK
News
- Digital Pharmaceutical Supply Chain Market 2024 Exclusive Report by InsightAce Analytic [Yahoo! Finance]Yahoo! Finance
- Vendor-Neutral Archive (VNA) & Picture Archiving and Communication System (PACS) Market Outlook, 2024-2028 & 2033, Featuring McKesson, Dell, Siemens - Rise in Cloud-based VNAs and AI Integration [Yahoo! Finance]Yahoo! Finance
- DID YOU PURCHASE AND/OR INGEST U-DREAM IN CANADA ON OR AFTER AUGUST 18, 2014? [Yahoo! Finance]Yahoo! Finance
- McKesson Co. (NYSE: MCK) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $547.00 to $545.00. They now have a "buy" rating on the stock.MarketBeat
- McKesson Co. (NYSE: MCK) had its price target raised by analysts at Wells Fargo & Company from $502.00 to $551.00. They now have an "equal weight" rating on the stock.MarketBeat
MCK
Earnings
- 5/7/24 - Miss
MCK
Sec Filings
- 5/14/24 - Form 4
- 5/10/24 - Form 144
- 5/8/24 - Form 10-K
- MCK's page on the SEC website